NX-04

NX-04 is a preclinical antibody-based therapeutic candidate being developed by Beijing Neoletix Biological Technology for the treatment of acute bleeding episodes in patients with Hemophilia A. Hemophilia A is a hereditary bleeding disorder caused by a deficiency or defect in coagulation Factor VIII, which is essential for the blood clotting process. Unlike many existing antibody therapies for hemophilia that are primarily used for prophylaxis, NX-04 is specifically targeted toward managing acute bleeding events. As of current reports, the specific molecular target of the antibody has not been disclosed by the developer, though it is part of a specialized pipeline focused on coagulation and hemostasis.